Supera self-expanding stents for endovascular treatment of femoropopliteal disease: a review of the clinical evidence

Kalkidan Bishu, Ehrin J Armstrong, Kalkidan Bishu, Ehrin J Armstrong

Abstract

Femoropopliteal lesions account for a significant proportion of endovascular interventions for peripheral artery disease in patients with disabling claudication or chronic limb ischemia. The femoropopliteal artery crosses two joint structures (hip and knee joints) and courses through the muscular adductor canal in the thigh, which places the artery at increased biomechanical stress. There is a critical need for stent platforms with a reduced risk of stent fracture while maintaining patency during long-term follow-up. The Supera peripheral stent system has a braided nickel-titanium alloy stent designed to withstand the unique stressors along the course of the femoropopliteal artery. This design may be associated with improved patency in association with reduced stent fracture rates on short- and medium-term follow-up. Further studies, including randomized controlled studies, comparing the Supera interwoven nickel-titanium alloy stent system with other stent platforms and angioplasty alone are needed.

Keywords: SUPERA interwoven nitinol stent; femoropopliteal atherosclerosis; peripheral artery disease; stent fracture.

Figures

Figure 1
Figure 1
Focal chronic occlusion in an above-knee segment of the popliteal artery (A) treated with a 5.5×40 mm Supera stent (B) without significant residual stenosis (C).
Figure 2
Figure 2
Moderately calcified right SFA (A) with severe stenosis in the middle segment (digital subtraction angiography) (B) treated with a 5.5×150 mm Supera stent (C) with no significant residual stenosis (D). Abbreviation: SFA, superficial femoral artery.
Figure 3
Figure 3
Severely calcified right SFA (A) with severe stenosis in the proximal and middle segment (B) treated with overlapping 5.5×150 mm and 5.5×60 mm Supera stents (C) with no significant residual stenosis (D). Abbreviation: SFA, superficial femoral artery.
Figure 4
Figure 4
Severely calcified left SFA with an prior distal SFA stent (A) with severe calcification and stenosis proximal (mid SFA) and distal (popliteal above knee) to the previous stent segment (B) treated with overlapping 5.5×150 mm Supera stent proximal to the old stent (C) and a 5×100 mm Supera stent distal to the old stent (D) with no significant residual stenosis (E and F). Abbreviation: SFA, superficial femoral artery.

References

    1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. American Association for Vascular Surgery. Society for Vascular Surgery. Society for Cardiovascular Angiography and Interventions. Society for Vascular Medicine and Biology. Society of Interventional Radiology. ACC/AHA Task Force on Practice Guidelines. American Association of Cardiovascular and Pulmonary Rehabilitation. National Heart, Lung, and Blood Institute. Society for Vascular Nursing. TransAtlantic Inter-Society Consensus. Vascular Disease Foundation ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol. 2006;113(11):e463–e654.
    1. Rooke TW, Hirsch AT, Misra S, et al. Society for Cardiovascular Angiography and Interventions. Society of Interventional Radiology. Society for Vascular Medicine. Society for Vascular Surgery 2011 ACCF/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(19):2020–2045.
    1. European Stroke Organisation. Tendera M, Aboyans V, et al. ESC Committee for Practice Guidelines. ESC guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC) Eur Heart J. 2011;32(22):2851–2906.
    1. Goodney PP, Beck AW, Nagle J, Welch HG, Zwolak RM. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50(1):54–60.
    1. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol. 2005;45(2):312–315.
    1. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther. 2009;16(3):261–269.
    1. Bosiers M, Deloose K, Callaert J, et al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54(4):1042–1050.
    1. Davaine JM, Azéma L, Guyomarch B, et al. One-year clinical outcome after primary stenting for Trans-Atlantic Inter-Society Consensus (TASC) C and D femoropopliteal lesions (the STELLA “STEnting Long de L’Artère fémorale superficielle” cohort) Eur J Vasc Endovasc Surg. 2012;44(4):432–441.
    1. FDA Supera Peripheral Stent System: Instruction for use. [Accessed May 21, 2015]. Available from: .
    1. Scheinert D, Grummt L, Piorkowski M, et al. A novel self-expanding interwoven nitinol stent for complex femoropopliteal lesions: 24-month results of the SUPERA SFA registry. J Endovasc Ther. 2011;18(6):745–752.
    1. Garcia L, Jaff MR, Metzger C, et al. SUPERB Trial Investigators* Wire-interwoven nitinol stent outcome in the superficial femoral and proximal popliteal arteries: twelve-month results of the SUPERB trial. Circ Cardiovasc Interv. 2015;8(5):e000937.
    1. Werner M, Paetzold A, Banning-Eichenseer U, et al. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results from the Leipzig SUPERA 500 registry. EuroIntervention. 2014;10(7):861–868.
    1. Dumantepe M, Seren M, Fazlıogullari O, Ayoglu U, Teymen B. Treatment of complex atherosclerotic femoropopliteal artery disease with a self-expanding interwoven nitinol stent: midterm results. Vascular. 2015 Epub ahead of print.
    1. Chan YC, Cheng SW, Ting AC, Cheung GC. Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents. J Vasc Surg. 2014;59(2):384–391.
    1. George JC, Rosen ES, Nachtigall J, VanHise A, Kovach R. SUPERA interwoven nitinol stent outcomes in above-knee IntErventions (SAKE) study. J Vasc Interv Radiol. 2014;25(6):954–961.
    1. Laird JR, Katzen BT, Scheinert D, et al. RESILIENT Investigators Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv. 2010;3(3):267–276.
    1. Dake MD, Ansel GM, Jaff MR, et al. Zilver PTX Investigators. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv. 2011;4(5):495–504.
    1. Geraghty PJ, Mewissen MW, Jaff MR, Ansel GM, VIBRANT Investigators Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. J Vasc Surg. 2013;58(2):386–395. e4.
    1. Werner M, Piorkowski M, Thieme M, et al. SUMMIT registry: one-year outcomes after implantation of the EPIC self-expanding nitinol stent in the femoropopliteal segment. J Endovasc Ther. 2013;20(6):759–766.
    1. Laird JR, Jain A, Zeller T, et al. Complete SE Investigators. Nitinol stent implantation in the superficial femoral artery and proximal popliteal artery: twelve-month results from the complete SE multicenter trial. J Endovasc Ther. 2014;21(2):202–212.
    1. Scheinert D, Werner M, Scheinert S, et al. Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent. JACC Cardiovasc Interv. 2013;6(1):65–71.
    1. Brescia AA, Wickers BM, Correa JC, Smeds MR, Jacobs DL. Stenting of femoropopliteal lesions using interwoven nitinol stents. J Vasc Surg. 2015;61(6):1472–1478.
    1. Goltz JP, Ritter CO, Kellersmann R, Klein D, Hahn D, Kickuth R. Endovascular treatment of popliteal artery segments P1 and P2 in patients with critical limb ischemia: initial experience using a helical nitinol stent with increased radial force. J Endovasc Ther. 2012;19(3):450–456.
    1. León LR, Jr, Dieter RS, Gadd CL, et al. Preliminary results of the initial United States experience with the Supera woven nitinol stent in the popliteal artery. J Vasc Surg. 2013;57(4):1014–1022.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅